Table 2

Lines of therapy as well as time since initial diagnosis until initiation of LEN and PEM combination therapy

PatientLines of therapy prior to LEN/PEMPFSTime since diagnosis till initiation of LEN/PEM therapy in months
1
  1. Sorafenib

  2. Mitotane, etoposide, doxorubicin, and cisplatin

  3. PD-1 inhibitor (nivolumab) and radiotherapy

  4. ACAT inhibitor

  5. Wee-1 inhibitor

  6. Cabozantinib

  7. PD-1 inhibitor (PEM) and LAG-3 inhibitor

  8. Gemcitabine and capecitabine

  9. LEN (single-agent)

2 months
6 months

4 months

3 months
4 months
2 months
4 months

4 months
12 months
56 months
2
  1. Mitotane

  2. PD-1 inhibitor (nivolumab)

  3. CSF-1R inhibitor and PD-1 inhibitor (PEM)

  4. Etoposide, doxorubicin, and cisplatin

7 months
5 months
2 months

2 months
66 months
3
  1. Mitotane

  2. Etoposide, doxorubicin, and cisplatin

  3. Ipilimumab and PD-1 inhibitor (nivolumab)

  4. LEN (single-agent)

36 months
1 month

2 months

6 months
68 months
4
  1. Mitotane and adjuvant radiotherapy

  2. Mitotane, etoposide, doxorubicin, and cisplatin

  3. PD-1 inhibitor (PEM)

  4. Carboplatin, etoposide, and mitotane

  5. Cabozantinib

18 months

13 months

6 months
13 months

6 months
86 months
5
  1. Mitotane, etoposide, doxorubicin, and cisplatin

  2. Mitotane (single-agent)

  3. PI3K inhibitor and PD-1 inhibitor (nivolumab)

  4. Cabozantinib

7 months

5 months
4 months

2 months
29 months
6
  1. Etoposide, doxorubicin, and cisplatin

  2. Etoposide

  3. Gemcitabine and docetaxel

  4. Cyclophosphamide, vincristine, and dacarbazine

  5. PD-1 inhibitor (PEM)

6 months

3 months
1 month
2 months

1 month
24 months
7
  1. Etoposide, doxorubicin, and cisplatin

  2. Gemcitabine and docetaxel

1 month

1 month
5 months
8
  1. Mitotane and adjuvant radiotherapy

  2. Mitotane, etoposide, doxorubicin, and cisplatin

  3. Gemcitabine and docetaxel

  4. LEN (single-agent)

4 months

1 month

3 months
1 month
10.5 months
  • LEN, lenvatinib; PEM, pembrolizumab; PFS, progression-free survival.